DMTK - DermTech adds 39% on TRICARE coverage

• Molecular diagnostic company DermTech ( NASDAQ: DMTK ) is on track to record its higher-ever intraday gain on Tuesday after announcing that a foundational assay in its DermTech Melanoma Test has been recommended for TRICARE coverage.
• Defense Health Agency’s Lab Joint Working Group has made the recommendation to TRICARE, a healthcare program targeted at U.S. service members, retirees, and their families.
• “This coverage recommendation makes the foundational assay of the DMT available to TRICARE’s approximately 9 million members and beneficiaries of the Military Health System,” the company said.
• DermTech ( DMTK ) also announced its total covered lives in the U.S. has reached ~113M, including 68M for Medicare/Medicare Advantage and 45M for commercial and governmental payers.
• In November, the company announced plans to engage commercial payers to add 30M – 50M covered lives by the end of Q1 2023.

For further details see: